Federal Register / Vol. 62, No. 53 / Wednesday, March 19, 1997 / Rules and Regulations 12951

assembly, as applicable. Repetitive

inspections are no longer required on an

MLG ‘‘A’’ frame assembly incorporating this

design configuration. Repetitive inspections

are still required on an MLG ‘‘A’’ frame

assembly if it does not incorporate this

improved design configuration.

(c) Installing both P/N 105–810023–75

(left) and P/N 105–810023–76 (right) MLG

‘‘A’’ frame assemblies eliminates the

repetitive inspection requirement of this AD.

(d) Special flight permits may be issued in

accordance with sections 21.197 and 21.199

of the Federal Aviation Regulations (14 CFR

21.197 and 21.199) to operate the airplane to

a location where the requirements of this AD

can be accomplished.

(e) An alternative method of compliance or

adjustment of the compliance time that

provides an equivalent level of safety may be

approved by the Manager, Wichita Aircraft

Certification Office (ACO), 1801 Airport

Road, Room 100, Mid-Continent Airport,

Wichita, Kansas 67209. The request shall be

forwarded through an appropriate FAA

Maintenance Inspector, who may add

comments and then send it to the Manager,

Wichita ACO.

Note 2: Information concerning the

existence of approved alternative methods of

compliance with this AD, if any, may be

obtained from the Wichita ACO.

(f) The inspection required by this AD shall

be done in accordance with Raytheon

Mandatory Service Bulletin No. 2361,

Revision III, dated June 1996. This

incorporation by reference was approved by

the Director of the Federal Register in

accordance with 5 U.S.C. 552(a) and 1 CFR

part 51. Copies may be obtained from the

Raytheon Aircraft Company, P.O. Box 85,

Wichita, Kansas 67201–0085. Copies may be

inspected at the FAA, Central Region, Office

of the Assistant Chief Counsel, Room 1558,

601 E. 12th Street, Kansas City, Missouri, or

at the Office of the Federal Register, 800

North Capitol Street, NW., suite 700,

Washington, DC.

(g) This amendment (39–9967) supersedes

AD 91–14–14, Amendment 39–7055.

(h) This amendment (39–9967) becomes

effective on May 16, 1997. Issued in Kansas

City, Missouri, on March 6, 1997.

Michael Gallagher,

Manager, Small Airplane Directorate, Aircraft

Certification Service.

[FR Doc. 97–6539 Filed 3–18–97; 8:45 am]

BILLING CODE 4910–13–U

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

21 CFR Part 73

[Docket No. 91C–0189]

Listing of Color Additives for Coloring

Contact Lenses; 1,4-Bis[(2-

hydroxyethyl)amino]-9,10-

anthracenedione bis(2-propenoic)ester

copolymers; Confirmation of Effective

Date

AGENCY: Food and Drug Administration,

HHS.

ACTION: Final rule; confirmation of

effective date.

SUMMARY: The Food and Drug

Administration (FDA) is confirming the

effective date of November 5, 1996, for

the final rule that amended the color

additive regulations to provide for the

safe use of the colored reaction products

formed by copolymerizing 1,4-bis[(2-

hydroxyethyl)amino]-9,10-

anthracenedione bis(2-propenoic)ester

either with glyceryl methacrylate/

methyl methacrylate/ethylene glycol

dimethacrylate monomers or with N,Ndimethyl acrylamide/methyl

methacrylate/ethylene glycol

dimethacrylate monomers to form

contact lenses.

DATES: Effective date confirmed:

November 5, 1996.

FOR FURTHER INFORMATION CONTACT:

Helen R. Thorsheim, Center for Food

Safety and Applied Nutrition (HFS–

216), Food and Drug Administration,

200 C St. SW., Washington, DC 20204,

202–418–3092.

SUPPLEMENTARY INFORMATION: In the

Federal Register of October 3, 1996 (61

FR 51584), FDA amended 21 CFR part

73 to provide for the safe use of the

colored reaction products formed by

copolymerizing 1,4-bis[(2-

hydroxyethyl)amino]-9,10-

anthracenedione bis(2-propenoic)ester

either with glyceryl methacrylate/

methyl methacrylate/ethylene glycol

dimethacrylate monomers or with N,Ndimethyl acrylamide/methyl

methacrylate/ethylene glycol

dimethacrylate monomers to form

contact lenses.

FDA gave interested persons until

November 4, 1996, to file objections or

requests for a hearing. The agency

received no objections or requests for a

hearing on the final rule. Therefore,

FDA finds that the final rule published

in the Federal Register of October 3,

1996, should be confirmed.

List of Subjects in 21 CFR Part 73

Color additives, Cosmetics, Drugs,

Medical devices.

Therefore, under the Federal Food,

Drug, and Cosmetic Act (secs. 201, 401,

402, 403, 409, 501, 502, 505, 601, 602,

701, 721 (21 U.S.C. 321, 341, 342, 343,

348, 351, 352, 355, 361, 362, 371, 379e))

and under authority delegated to the

Commissioner of Food and Drugs (21

CFR 5.10), notice is given that no

objections or requests for a hearing were

filed in response to the October 3, 1996,

final rule. Accordingly, the amendments

promulgated thereby became effective

November 5, 1996.

Dated: March 5, 1997.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 97–6849 Filed 3–18–97; 8:45 am]

BILLING CODE 4160–01–F

21 CFR Part 558

New Animal Drugs for Use in Animal

Feeds; Bacitracin Methylene

Disalicylate and Chlortetracycline

AGENCY: Food and Drug Administration,

HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug

Administration (FDA) is amending the

animal drug regulations to reflect

approval of a new animal drug

application (NADA) filed by Alpharma

Inc. The NADA provides for using

currently approved, single ingredient,

Type A medicated articles in making

combination drug, Types B and C

medicated, swine feeds containing

bacitracin methylene disalicylate and

chlortetracycline. The Type C

medicated feed is used for increased

rate of weight gain and improved feed

efficiency due to the activity of

bacitracin, and treatment of enteritis

and pneumonia caused by certain

bacteria susceptible to chlortetracycline.

EFFECTIVE DATE: March 19, 1997.

FOR FURTHER INFORMATION CONTACT:

George K. Haibel, Center for Veterinary

Medicine (HFV–133), Food and Drug

Administration, 7500 Standish Pl.,

Rockville, MD 20855, 301–594–1644.

SUPPLEMENTARY INFORMATION: Alpharma

Inc., One Executive Dr., Fort Lee, NJ

07024, filed NADA 141–059, which

provides for combining separately

approved, Type A medicated articles

containing BMD (bacitracin methylene

disalicylate (bacitracin MD)) and CTC

(chlortetracycline) in making

combination drug, Type C medicated

swine feed. The Type C medicated feed